[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Dips",
                    "Broader Markets"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "AbbVie Selloff Overdone, Stock Remains Undervalued: BMO",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Selloff",
                    "Undervalued",
                    "BMO"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Selloff Overdone, Stock Remains Undervalued: BMO",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie",
            "features": {
                "keywords": [
                    "REGENXBIO",
                    "Stock Up",
                    "Collaboration Deal",
                    "AbbVie"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Co-Develop",
                    "Regenxbio",
                    "Gene Therapy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal",
            "features": {
                "keywords": [
                    "Gene Therapy",
                    "Stocks",
                    "Focus",
                    "AbbVie/Regenxbio Deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?",
            "features": {
                "keywords": [
                    "REGENXBIO",
                    "Moves",
                    "Higher",
                    "Strength"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]